Theralase Technologies Inc.

Presenter: Roger Dumoulin-White, President & CEO

Company Information

Company Type: Medical Technologies

Development Stage: Public

Company Profile

Theralase Technologies Inc. designs, develops and manufactures patented, super-pulsed laser technology utilized in bio-stimulation and bio-destruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular skeletal conditions and wound care. When combined with patented light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, and viruses. To learn more about Theralase, contact Roger Dumoulin-White, President and CEO of Theralase Technologies at 1 866 843 5273 or rwhite@theralase.com.

Presenter Bio

Roger Dumoulin-White, Professional Engineer, founder, President & CEO of Theralase Technologies Inc., traded in his management role at the electronics division of Ford Motor Company to pursue an unproven venture that is now shifting the paradigm of modern medicine. Based on the recommendation of his father, Roger used his accrued vacation days to travel overseas and investigate the technology his father so enthusiastically promoted after discovering it 18 months earlier. After visiting multiple clinics, speaking to countless physicians and patients and seeing the extraordinary results first hand, Roger concluded that the efficacy of laser healing was undeniable and thus envisioned a business.

Theralase began in 1995, with one employee assembling and selling a highly technical superpulsed cold laser system from the tiles of his kitchen floor. A small but stable one man show soon ignited the interest of some prominent clinicians and spawned a fertile therapeutic laser market. Roger, with his eye on the prize, knew he could not compete in the emerging laser market without additional assistance. He set out and told his story to a few of Torontos well heeled, who were remarkably eager to secure a slice of the future.

Roger took Theralase public in May of 2004 and has since turned his small venture into a multimillion dollar enterprise. To boast of his accolades, Roger has unveiled two product upgrades, secured multiple patents on revolutionary laser enhancements, and purchased the worldwide rights to a promising new cancer destruction molecule, which is currently being evaluated at the renowned Princess Margaret Hospital. Theralase has positioned itself as a secure investment and a rising star of modern medicine.

Contact

Theralase Technologies Inc.
29 Gervais Drive, Suite 102
Toronto
Ontario, Canada
M3C 1Y9

ph: 416-447-8455 x225
fx: 416-447-3020

www.theralase.com
rwhite@theralase.com